Ubs Group Ag Chroma Dex Corp. Transaction History

Ubs Group Ag

$611 Billion
Q3 2025

A detailed history of Ubs Group Ag transactions in Chroma Dex Corp. stock. As of the latest transaction made, Ubs Group Ag holds 1,196,097 shares of CDXC stock, worth $7.34 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,196,097

Previous 85,656 1296.4%

Holding current value

$7.34 Million

Previous $525,000 1298.86%

% of portfolio

0.0%

Previous 0.0%

35 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 13, 2025	BUY	N/A	1,110,441 Added 1296.4%	1,196,097 $7.34 Million
Q2 2025 Aug 14, 2025	BUY	$5.42 - $7.08 $165,418 - $216,081	30,520 Added 55.35%	85,656 $525,000
Q1 2025 May 13, 2025	BUY	$5.26 - $8.55 $56,087 - $91,168	10,663 Added 23.98%	55,136 $380,000
Q4 2024 Feb 14, 2025	SELL	$3.25 - $7.72 $46,852 - $111,291	-14,416 Reduced 24.48%	44,473 $236,000
Q3 2024 Nov 14, 2024	SELL	$2.51 - $3.8 $202,951 - $307,256	-80,857 Reduced 57.86%	58,889 $214,000

Q2 2024 Aug 13, 2024	BUY	$2.44 - $4.32 $292,124 - $517,203	119,723 Added 597.93%	139,746 $381,000
Q1 2024 May 13, 2024	BUY	$1.36 - $3.84 $25,255 - $71,308	18,570 Added 1278.05%	20,023 $69,000
Q4 2023 Feb 09, 2024	BUY	$1.28 - $1.6 $504 - $630	394 Added 37.2%	1,453 $2,000
Q3 2023 Nov 09, 2023	SELL	$1.36 - $1.77 $7,435 - $9,676	-5,467 Reduced 83.77%	1,059 $1,000
Q2 2023 Aug 11, 2023	SELL	$1.31 - $1.79 $14,526 - $19,849	-11,089 Reduced 62.95%	6,526 $10,000
Q1 2023 May 12, 2023	BUY	$1.48 - $2.19 $304 - $451	206 Added 1.18%	17,615 $26,000
Q4 2022 Feb 08, 2023	SELL	$1.25 - $1.94 $8,125 - $12,610	-6,500 Reduced 27.19%	17,409 $29,000
Q3 2022 Nov 10, 2022	SELL	$1.19 - $2.06 $614 - $1,062	-516 Reduced 2.11%	23,909 $29,000
Q2 2022 Aug 10, 2022	BUY	$1.59 - $2.7 $4,372 - $7,425	2,750 Added 12.69%	24,425 $41,000
Q1 2022 May 16, 2022	SELL	$2.02 - $3.92 $67,334 - $130,669	-33,334 Reduced 60.6%	21,675 $53,000
Q4 2021 Feb 14, 2022	BUY	$3.74 - $6.7 $8,934 - $16,006	2,389 Added 4.54%	55,009 $206,000
Q3 2021 Nov 15, 2021	SELL	$6.05 - $10.41 $283,146 - $487,198	-46,801 Reduced 47.07%	52,620 $330,000
Q2 2021 Aug 13, 2021	BUY	$6.66 - $10.92 $323,789 - $530,897	48,617 Added 95.7%	99,421 $980,000
Q1 2021 May 12, 2021	SELL	$4.59 - $18.74 $465,839 - $1.9 Million	-101,490 Reduced 66.64%	50,804 $474,000
Q4 2020 Feb 11, 2021	BUY	$3.93 - $5.5 $6,657 - $9,317	1,694 Added 1.12%	152,294 $731,000
Q3 2020 Nov 12, 2020	SELL	$4.01 - $5.56 $205,636 - $285,122	-51,281 Reduced 25.4%	150,600 $604,000
Q2 2020 Jul 31, 2020	SELL	$3.0 - $5.52 $55,614 - $102,329	-18,538 Reduced 8.41%	201,881 $926,000
Q1 2020 May 01, 2020	SELL	$2.54 - $4.75 $44,462 - $83,148	-17,505 Reduced 7.36%	220,419 $719,000
Q4 2019 Feb 14, 2020	BUY	$2.83 - $4.61 $79,157 - $128,946	27,971 Added 13.32%	237,924 $1.03 Million
Q3 2019 Nov 14, 2019	BUY	$3.83 - $4.72 $62,291 - $76,766	16,264 Added 8.4%	209,953 $826,000
Q2 2019 Aug 14, 2019	SELL	$3.71 - $4.83 $4,678 - $6,090	-1,261 Reduced 0.65%	193,689 $900,000
Q1 2019 May 14, 2019	BUY	$3.2 - $4.19 $136,342 - $178,523	42,607 Added 27.97%	194,950 $817,000
Q4 2018 Feb 14, 2019	BUY	$2.8 - $4.22 $20,386 - $30,725	7,281 Added 5.02%	152,343 $523,000
Q3 2018 Nov 14, 2018	SELL	$3.5 - $4.91 $2,247 - $3,152	-642 Reduced 0.44%	145,062 $623,000
Q2 2018 Aug 14, 2018	BUY	$3.22 - $4.43 $78,220 - $107,613	24,292 Added 20.01%	145,704 $541,000
Q1 2018 May 15, 2018	BUY	$4.05 - $6.46 $238,334 - $380,158	58,848 Added 94.06%	121,412 $510,000
Q4 2017 Feb 14, 2018	BUY	$3.88 - $6.96 $106,948 - $191,845	27,564 Added 78.75%	62,564 $368,000
Q3 2017 Nov 14, 2017	BUY	$2.91 - $4.71 $63,120 - $102,164	21,691 Added 162.98%	35,000 $151,000
Q2 2017 Aug 14, 2017	SELL	N/A	-6,174 Reduced 31.69%	13,309 $51,000
Q1 2017 Nov 14, 2017	BUY	N/A	19,483	19,483 $52,000

Others Institutions Holding CDXC

# of Institutions

174

Shares Held

30.9M

Call Options Held

121K

Put Options Held

55.6K

View Full List

About ChromaDex Corp.

Ticker CDXC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,350,896
Market Cap $420M
Description
ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingre...

More about CDXC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account